Skip to contentB
Bio-Rad Laboratories, Inc.
B
BIOBio-Rad Laboratories, Inc. Q1 2021 · 10-Q
Revenue$726.80M$726.80M+27.1% vs Q1 2020 Net Income$980.00M$980.00M+42.9% vs Q1 2020 EPS Diluted$32.46$32.46+42.9% vs Q1 2020 Gross Profit$400,500,000+26.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Bio-Rad Laboratories, Inc. · CIK 12208 · Engraved from SEC EDGAR
Operating Cash Flow$113,610,000+80.9% Free Cash Flowderived$94,063,000+128.2% Margins · derivedGross margin55.1%−0.4 pt vs Q1 2020
Operating margin13.9%+0.9 pt vs Q1 2020
Net margin134.8%+14.9 pt vs Q1 2020
ended Mar 31, 2021 · filed Apr 30, 2021 · 30 d after period end